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Abstract
Background:  Propanil is an important cause of death from acute pesticide poisoning, of which
methaemoglobinaemia is an important manifestation. However, there is limited information about the
clinical toxicity and kinetics. The objective of this study is to describe the clinical outcomes and kinetics of
propanil following acute intentional self-poisoning.
Methods: 431 patients with a history of propanil poisoning were admitted from 2002 until 2007 in a large,
multi-centre prospective cohort study in rural hospitals in Sri Lanka. 40 of these patients ingested propanil
with at least one other poison and were not considered further. The remaining 391 patients were classified
using a simple grading system on the basis of clinical outcomes; methaemoglobinaemia could not be
quantified due to limited resources. Blood samples were obtained on admission and a subset of patients
provided multiple samples for kinetic analysis of propanil and the metabolite 3,4-dichloroaniline (DCA).
Results: There were 42 deaths (median time to death 1.5 days) giving a case fatality of 10.7%. Death
occurred despite treatment in the context of cyanosis, sedation, hypotension and severe lactic acidosis
consistent with methaemoglobinaemia. Treatment consisted primarily of methylene blue (1 mg/kg for one
or two doses), exchange transfusion and supportive care when methaemoglobinaemia was diagnosed
clinically. Admission plasma concentrations of propanil and DCA reflected the clinical outcome. The
elimination half-life of propanil was 3.2 hours (95% confidence interval 2.6 to 4.1 hours) and the
concentration of DCA was generally higher, more persistent and more variable than propanil.
Conclusion: Propanil is the most lethal herbicide in Sri Lanka after paraquat. Methylene blue was largely
prescribed in low doses and administered as intermittent boluses which are expected to be suboptimal
given the kinetics of methylene blue, propanil and the DCA metabolite. But in the absence of controlled
studies the efficacy of these and other treatments is poorly defined. More research is required into the
optimal management of acute propanil poisoning.
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Background
Propanil (3,4-dichloropropionanilide) is a selective acy-
lanilide herbicide used widely in rice cultivation in many
parts of the world. It may be the most extensively used
herbicide for rice production worldwide [1] and is ranked
within the top 20 pesticides used for agriculture in the
United States.[2] Unfortunately, acute self-poisoning
leading to severe poisoning and death has been reported
with propanil, particularly in Asia where subsistence farm-
ing is more common. [3-10] Death is largely attributed to
severe methaemoglobinaemia that is prolonged and treat-
ment-resistant. It is not known whether these published
cases are representative of the usual outcome from acute
propanil poisoning or why current medical care is of lim-
ited efficacy.
Propanil is hydrolysed in vivo to 3,4-dichloroaniline
(DCA) which is in turn oxidised to 3,4-dichlorophenylhy-
droxylamine which is a potent inducer of methaemo-
globin, figure 1. [11-15] These reactions are similar to
those of dapsone which are well characterised: the severity
of methaemoglobinaemia relates to the amount of dap-
sone's hydroxylamine metabolite, which varies with dose
and cytochrome P450 activity.[16,17] We therefore expect
that there will be a proportional relationship between the
concentration of propanil and its metabolites and clinical
toxicity, although this has not yet been confirmed in
humans.
The objective of this study is to describe the clinical out-
comes of acute intentional self-poisoning from propanil
in a large, multi-centre prospective cohort study in general
hospitals in Sri Lanka. The relationship between the
admission concentration of propanil and 3,4-dichloro-
aniline, and some details on their kinetics will also be
assessed, in particular their relationship to clinical toxic-
ity.
Methods
Clinical
The South Asian Clinical Toxicology Research Collabora-
tion is conducting clinical studies on acute poisoning in
Sri Lankan rural hospitals where the incidence of inten-
tional self-poisoning is high.[18] Patients were included
in this analysis if they presented to a study hospital with a
history of acute propanil poisoning. Most patients were
recruited from Anuradhapura Teaching Hospital (187
consecutive patients between 5th April 2002 and 13th April
2007) and Polonnaruwa General Hospital (242 consecu-
tive patients presenting between 7th June 2002 and 7th
April 2007). These patients presented to each hospital
directly or via transfer from a district hospital where they
had been medically reviewed. Resources are limited in
these rural hospitals, however, they do provide 24-hour
medical and nursing care to patients in dedicated general
medical wards.
Patients were identified by on-site study doctors on pres-
entation. Following the initial clinical assessment all
patients provided an admission blood sample which was
used to confirm the exposure reported on history. Some
patients provided additional blood samples because they
were recruited into one of two studies:
1 RCT1: ISRCTN02920054 is a randomised controlled
trial (RCT) evaluating the efficacy of oral superactivated
charcoal in acute poisoning. Patients were allocated to a
regimen of superactivated charcoal (single dose activated
charcoal, multiple doses of activated charcoal, or no acti-
vated charcoal) using a stratified randomisation protocol
based on time since poisoning and clinical toxicity on
admission. Propanil was included with other miscellane-
ous pesticides during randomisation. This study was com-
pleted in 2005 and did not demonstrate a clinical benefit
from charcoal.[19]
Metabolism of propanil in vivo, including the clinical toxicity  associated with each metabolite Figure 1
Metabolism of propanil in vivo, including the clinical 
toxicity associated with each metabolite. [11-15]*. * 
Propanil (CAS No. 709-98-8) is also classified as a chloro-
aniline herbicide and known as DCPA, propanide and N-(3,4-
dichlorophenyl)propanamide. It is stable in solution at pH 3 – 
9 but may be subject to hydrolysis to 3,4-dichloroaniline and 
propionic acid outside this range, although this has been 
debated. If hydrolysis occurs to a significant extent in the acid 
medium of the gastrointestinal tract there may be a dimin-
ished importance for esterases for metabolism of propanil. 
The specific esterases that hydrolyse propanil to DCA have 
not been identified but are known to be inhibited by 
paraoxon and sodium fluoride. A minor metabolite of 
CYP450 oxidation of DCA is 6-hydroxy-dichloroaniline 
which is less toxic.[13].
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2 Pharmacokinetic (PK) study: This study followed RCT1.
Patients with acute pesticide poisoning presenting to
study hospitals consented to provide multiple blood sam-
ples during admission, as detailed below. Patients were
administered activated charcoal at the discretion of the
treating physician.
Ethics approval for the above studies was obtained from
the Universities of Colombo (Sri Lanka), Oxford (United
Kingdom), Peradeniya (Sri Lanka), Australian National
University (Australia) and/or Sri Lankan Medical Associa-
tion (Sri Lanka). Written informed consent was obtained
for the two studies with multiple blood sampling.
The history of exposure (including co-ingestants) and
clinical details were obtained on presentation for each
patient. Patients were regularly reviewed and prospec-
tively determined clinical details were recorded by on-site
study doctors until discharge or death. Severity of poison-
ing was graded on the basis of predetermined clinical cri-
teria using a simple system (table 1). Co-oximetry for
quantification of methaemoglobinaemia was not availa-
ble for the duration of the study given resource limitations
in these rural hospitals. Blood gas analysis was available
for a short period of time in one of the study hospitals and
these measurements were used to support clinical man-
agement.
To obtain additional clinical information on the patients
who died, the medical notes were retrospectively reviewed
using a pre-designed data collection sheet by a clinical
trial coordinator at each centre.
The initial treatment of all patients with acute pesticide
poisoning consisted of resuscitation and gastrointestinal
decontamination. Patients were monitored clinically
(including pulse oximetry) and received supportive care
including supplemental oxygen, intravenous fluids and
ventilatory and haemodynamic (dopamine) support as
required. In the absence of co-oximetry analysis, signifi-
cant methaemoglobinaemia was diagnosed when there
was cyanosis that did not correct with high-flow oxygen
and ventilatory support in patients with a history of pro-
panil poisoning. Brown-red coloured blood was usually
noted if blood tests were obtained.
Treatment of methaemoglobinaemia was similar to local
guidelines.[20] This consisted initially of methylene blue
(methylthionium chloride) 1 mg/kg intravenous bolus
for 1–2 doses. This was followed by exchange transfusion
(infusion of one unit of cross-matched erythrocytes
together with removal of one unit from the patient) for
persistent clinical toxicity. In some patients laboratory
grade methylene blue was administered orally because the
intravenous formulation was unavailable; oral ascorbic
acid (1 g two or three times daily) was also administered
to some patients. These oral treatments were commenced
irrespective of whether they were administered activated
charcoal. Antibiotics (usually penicillin and metronida-
zole) were given when aspiration pneumonitis was sus-
pected clinically.
All interventions were determined by the treating medical
team irrespective of the patient's involvement in the stud-
ies. For the duration of these studies there were no major
changes in clinical management of patients with acute
propanil poisoning except that intravenous methylene
blue was intermittently unavailable. Given the heteroge-
neity of these patients (in particular the variable expo-
sures) and because this is an observational study, only
conservative interpretations of the efficacy of these treat-
ments are possible.
In addition to the admission blood sample, serial samples
were provided by a sub-group of patients enrolled in
RCT1 and all patients enrolled in PK study. Blood samples
were obtained on admission to hospital, then at 1, 4, 12,
and 24 hours after initial clinical assessment, then once
daily until discharge or death, as allowed by clinical fac-
tors. Samples were collected into an EDTA tube which was
promptly centrifuged and the plasma was removed and
frozen at -23°C until analysis of the concentration of pro-
panil and 3,4-dichloroaniline.
Laboratory
Laboratory analyses were conducted at the Walther-Straub
Institute of Pharmacology and Toxicology, Ludwig-Maxi-
milians University, Germany. Propanil and DCA (Pes-
tanal®  quality) were purchased from Riedel de Haen,
Seelze, Germany. Stock solutions (10 mM) were prepared
in 40% CH3CN/60% 10 mM ammonium acetate, pH 4.5
Table 1: Clinical grading of severity of acute propanil poisoning
Minor Asymptomatic or mild symptoms (usually gastrointestinal or sedation) with stable vital signs and no other organ involvement
Moderate to severe Poisoning requiring intervention (eg. clinical evidence of cyanosis, hypotension (MABP < 70 mmHg), hypoventilation requiring 
intubation, cardiac arrest or evidence of ischaemia, sedation or coma (GCS < 10), seizures, oliguria)
DeathBMC Clinical Pharmacology 2009, 9:3 http://www.biomedcentral.com/1472-6904/9/3
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(v/v) and mixed with blank heparinized plasma to give a
final concentration of 40 μM propanil and 4 μM DCA.
Plasma samples (100 μL) were treated with CH3CN (150
μL) for 15 min to minimize protein binding, followed by
centrifugation at 10 000 rpm for 15 min. After addition of
3 M trichloroacetic acid (50 μL) the mixture was vortexed
and centrifuged for another 15 min. 200 μl of the super-
natant was adjusted to pH 5 with 16 μL of a mixture of
conc. ammonium hydroxide and glacial acetic acid (2:1,
v/v). 20 μL of this mixture was subjected to HPLC on
LiChroSpher® 100 RP 15 (5 μm; 125 mm × 4 mm I.D.)
with a guard column LiChroCart® 4-4 (Merck, Darmstadt,
Germany). Isocratic elution was performed with 40%
CH3CN/60% 10 mM ammonium acetate, pH 4.5 (v/v) at
a flow rate of 1 mL/min and detection at 250 nm. Quan-
tification was achieved by comparison of the peak areas of
authentic plasma standards. The retention times of DCA
and propanil were 8.0 min and 9.4 min, respectively; the
limit of quantification (LOQ) was about 1 μM each.
Kinetics and the dose-response relationship of propanil 
and DCA
The kinetics of propanil and DCA were determined in
serial blood samples. The method of Beal was used to
incorporate concentrations below the LOQ (between 0
and 1 μM).[21] Here, the first concentration value below
the LOQ was fixed to 0.5 μM (0.5 × LOQ) and subsequent
samples were excluded from further analysis. Patients in
whom the concentration was not greater than the LOQ in
at least two samples were excluded from the kinetic anal-
ysis. The medical notes of the patients included in this
sub-study were reviewed (where available) to determine
whether exchange transfusion was administered since this
treatment has the potential to decrease the plasma con-
centration unrelated to endogenous clearance.[22]
Changes in the concentration of propanil and DCA during
admission were described for individual patients who
provided a sample on four or more occasions. An aver-
aged description of this relationship for the population
was then determined by comparing the ratio of pro-
panil:DCA concentrations for all samples and plotted rel-
ative to the time post-ingestion. Most of these initial
samples were obtained on admission or soon after, prior
to treatments such as exchange transfusion.
To determine the apparent elimination half-life for the
cohort as a whole, data obtained from all patients who
provided serial blood samples (more than two) were col-
lated. Data from each patient were plotted on a semi-log-
arithmic graph to determine if changes in concentration
were first order and the extent of variation within this
cohort. The best-fit apparent elimination half-life and
95% confidence interval was then determined by non-lin-
ear regression. This was performed by global fitting of the
rate constant in a monoexponential decay model (Ct =
Ci*exp(-k.t); where Ci is the initial concentration and Ct is
the concentration after time t when elimination occurs
with a rate constant of k). These analyses were performed
using GraphPad Prism version 4.03 for Windows, Graph-
Pad Software, San Diego CA USA. For propanil, only data
following an apparent Cmax were included in this regres-
sion.
The dose-response relationship was demonstrated graph-
ically by plotting the available concentration-time points
relative to the clinical outcome for the patient (table 1) for
both propanil and DCA.
Statistical analyses
Statistical analysis compared baseline clinical and demo-
graphic characteristics for patients in three groups: mild
poisoning, moderate-severe poisoning, and fatal poison-
ing, as defined in table 1. The chi-square test was used for
categorical variables and continuous nonparametric vari-
ables were compared using the Kruskal-Wallis test with
Dunn's multiple comparison test if P < 0.05. Receiver-
operator characteristic (ROC) curves were constructed to
demonstrate the sensitivity, specificity and likelihood
ratios of threshold values from clinical and demographic
variables for predicting death compared to survival. 2 × 2
tables were constructed to calculate sensitivity and specif-
icity at the best threshold (as determined by Youden's
index). Sensitivity is defined as the proportion of people
who died that were predicted to die, and specificity as the
proportion of people who survived that were predicted to
survive. Positive and negative likelihood ratios and pre-
dictive values were also calculated. All analyses were con-
ducted using GraphPad Prism and P < 0.05 was
considered statistically significant.
Results
There were 431 presentations with a history of acute pro-
panil poisoning over five years (5th April 2002 to 13th
April 2007). Of these patients, 40 had ingested at least one
other poison (30 of these were poisoned by a combina-
tion product containing propanil and another agent, usu-
ally clomazone, fentrazamide, pendimethalin or
thiobencarb) and 3 of these died. Patients with co-inges-
tions were not considered further.
A total of 356 blood samples were available for inclusion
in this study, including serial samples in 26 patients,
allowing kinetic analyses to be conducted.
Clinical outcomes
There were 42 deaths (median time to death 1.5 days; IQR
1.0–2.4 days) giving a case fatality of 10.7% (42/391; 95%
confidence interval 7.9–14.1%). Death occurred at stag-BMC Clinical Pharmacology 2009, 9:3 http://www.biomedcentral.com/1472-6904/9/3
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gered times post-ingestion which may relate to the
amount ingested (where larger ingestions died earlier,
although accurate dose information was not available)
with the majority occurring within 3 days, figure 2.
Patients who died were older, had a depressed GCS on
admission, and a higher concentration of propanil in the
admission blood sample (table 2). This was confirmed by
the ROC curves (figure 3) with areas under the ROC curve
of propanil concentration = 0.92, GCS = 0.88, age = 0.82.
Values predicting death were determined and their corre-
sponding sensitivity, specificity and likelihood ratios were
calculated (figure 3). The initial mean arterial blood pres-
sure and time to presentation did not appear to relate to
the clinical outcome (table 2 and figure 3); for blood pres-
sure, the area under the ROC curve = 0.68.
Nausea, vomiting, diarrhoea, tachycardia, dizziness and
confusion occurred but were not a prominent feature in
patients who did not develop severe poisoning. Some
patients initially demonstrated central nervous system
depression in the absence of documented hypoxia or cya-
nosis. Respiratory distress in the context of hypoxia on
pulse oximetry with focal respiratory crepitations soon
after presentation was considered to be aspiration pneu-
monitis; chest x-rays were not available to confirm this.
Four of the patients who died were asymptomatic on
admission but developed severe poisoning within 12
hours of ingestion and died between 1.2 and 2.4 days
post-ingestion.
Patients with severe poisoning demonstrated depression
of the central nervous system, hypotension and were clin-
ically cyanosed. Death occurred in these patients follow-
ing progressive hypotension in the context of cyanosis
with low oxygen saturation on pulse oximetry (SpO2 ~82–
85%), despite active management. Blood samples were
noted to be brown-red in colour. Blood gas analyses dem-
onstrated severe lactic acidosis despite normal arterial
oxygenation and hypocarbia consistently, suggesting tis-
sue hypoxia due to severe methaemoglobinaemia with
compensatory hyperventilation. Therefore, methaemo-
globinaemia appeared to be an important manifestation
of acute propanil poisoning.
Management
Patients were administered variable regimens of methyl-
ene blue, ascorbic acid and exchange transfusion. Occa-
sionally, methylene blue was given in the absence of
clinical cyanosis at the time of admission, which may
reflect the clinicians' anxiety regarding the potential for
severe poisoning from such an exposure. There is a per-
ception amongst some clinicians in Sri Lanka that methyl-
ene blue is of low efficacy for the treatment of acute
propanil poisoning.[10] This is reflected in the records of
patients who died, where only rarely were more than two
doses of methylene blue given to patients with severe poi-
soning. Instead, exchange transfusion was observed to be
applied more vigorously. The typical regimen was
exchange of 1 unit every 1–2 hours until recovery or
death, although most patients only received two or three
exchanges. In some patients there was deterioration in
blood pressure and respiratory failure following transfu-
sion which might relate to an adverse reaction of the
transfusion but it might also reflect the natural history of
severe poisoning following a massive ingestion.
Kinetics and the dose-response relationship of propanil 
and DCA
The concentration-time profiles of propanil and DCA for
six patients with the most samples are shown in figure 4.
First order elimination is noted in figures 4(a) to 4(c) and
the half-life of DCA is longer than propanil. The profile of
the lower three patients is less predictable. Allowing for a
lag-time, changes in the concentration of DCA often par-
allel those of propanil, as observed in A4796, P3408 and
P4717. Inter-individual differences in the apparent time-
lag between these changes may reflect varying activities of
the esterase required for metabolic activation (figure 1).
Table 2: Clinical outcomes, demographics and clinical features on admission
Severity of poisoning Minor Moderate to severe Death Statistical significance§
N/Total (%) 225/391 (57) 124/391 (32) 42/391 (11)
Gender (M:F) 139:86 64:60 34:8 P = 0.003
Age (years) 24 (20–34)*$ 22 (18–33)*$ 45 (37–54)$# $#P < 0.001; *P > 0.05
TTP (hours) 4.6 (2.7–-7.1) 5.3 (3.4–8.8) 4.5 (3.4–5.8) P = 0.1431
GCS 15 (15-15)*$ 15 (12–15)*$ 7 (3–13)$# $# *P < 0.0001
MABP (mmHg) 89 (82–97)$# 83 (76–90)*$ 78 (72–86)*#$ # P < 0.001; *P > 0.05
TTD (days) 2.2 (1.7–3.1)* 3.3 (2.6–5.0)* 1.5 (1.1–2.4) *P < 0.001
Admission propanil concentration (μM) 1.3 (0.0–7.7)$*
(n = 125)
8.9 (2.8–35.2)#*
(n = 67)
72.0(45.8–128.3)#$
(n = 19)
*$#P < 0.001
Median values and inter-quartile ranges (IQR) presented
§Superscript symbols (*, $, #) are used to link two values with their respective P-value.
TTP = time to present TTD = time to discharge or death
Glasgow Coma Score (GCS) and the mean arterial blood pressure (MABP) are at the time of presentation to hospitalBMC Clinical Pharmacology 2009, 9:3 http://www.biomedcentral.com/1472-6904/9/3
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The highest concentration of DCA generally exceeded that
of propanil and remained elevated for a longer period.
Most patients demonstrated a nonlinear concentration-
time curve for propanil and DCA on the semilogarithmic
graph, which may be consistent with ongoing absorption;
exceptions are shown in figure 4. Data on exchange trans-
fusion were only available in three patients in whom no
substantial change in elimination was noted.
Both propanil and DCA were quantified in 300 samples
allowing for temporal changes in the ratio of pro-
panil:DCA to be determined as shown in figure 5. It is
observed that prior to 10 hours post-ingestion the ratio
varies widely, which is probably due to ongoing propanil
absorption and bioconversion to DCA. After 10 hours,
however, the ratio is consistently less than 1.0 meaning
that the concentration of DCA is higher than propanil.
This could be due to propanil having higher clearance or
a larger volume of distribution (Vd) than DCA. However,
the observed half-life of DCA may also be strongly influ-
enced by the rate of formation from propanil (a type of
'flip-flop' kinetics[22]).
The concentration-time profiles of propanil and DCA for
26 individuals in whom serial samples were obtained are
shown in figure 6 relative to their clinical outcome. Many
patients demonstrate ongoing absorption of propanil
until around 10 hours post-ingestion which was followed
by an elimination phase. In survivors, by 36 hours post-
ingestion the concentration of DCA was low or negligible,
so clinical toxicity is not likely to increase beyond this
time (Figure 7). This contrasts to figure 4(d) where the
elimination of propanil was prolonged and the concentra-
tion of DCA increased from admission until death. The
reason for this difference is not apparent from this data,
and because this kinetic profile appears atypical it was
excluded from the regression analysis.
The median best-fit apparent elimination half life of pro-
panil was 3.2 hours (95% confidence interval 2.6 to 4.1
hours); figure 6. The decay curves of the patients are noted
to be approximately parallel, excluding two patients who
died. The spread of these profiles most likely reflects dif-
ferences in the bioavailable dose between patients. Two of
the patients shown in figure 6 were known to receive
exchange transfusion and their half-life did not appear to
differ from the others.
A half-life was not calculated for DCA because the change
in plasma concentration was highly variable. In some
individuals the concentration increased during the sam-
pling period while in the others it decreased. Therefore, a
best-fit line would not be expected to represent the popu-
lation. The increasing DCA concentrations at some late
time points suggest that formation is more rapid than
elimination, which may be more marked with higher con-
centrations of DCA, although this was not consistently
observed.
Admission plasma concentrations of propanil and DCA
reflect clinical outcomes, as shown in figure 8, which sup-
ports the findings in the ROC curve (figure 3). With the
exception of a few outliers, patients with the highest con-
centrations died and those with low levels demonstrated
Survival curve in patients with acute propanil poisoning Figure 2
Survival curve in patients with acute propanil poison-
ing.
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minor poisoning; both of these groups overlapped with
patients manifesting moderate-severe poisoning. The rela-
tionship was less marked for DCA during the first 6 hours
which probably relates to the time for bioconversion from
propanil.
Discussion
The mortality from acute intentional self-poisoning with
propanil is 10.7% (95% CI 7.9–14.1%) making it the
most lethal herbicide in Sri Lanka after paraquat. Clinical
toxicity is characterised by cyanosis, acidosis and progres-
sive end-organ dysfunction which are consistent with
severe and prolonged methaemoglobinaemia. This
reflects the elevated concentration of DCA that is subse-
quently metabolised to a hydroxylamine compound (fig-
ure 1) which appears to be the primary mediator of
clinical toxicity. The most common specific treatments of
methaemoglobinaemia were exchange transfusion and
methylene blue and on the basis of clinical experience the
former is considered more effective, but this could not be
determined in this study. However, methylene blue was
largely prescribed in low doses and administered as inter-
mittent boluses which may be suboptimal with large pro-
panil exposures. In the absence of controlled studies, the
efficacy of these and other treatments is poorly defined.
More research is required into the optimal management
of acute propanil poisoning.
The previous kinetic data for propanil and DCA are lim-
ited to laboratory animal studies and a single patient.
DCA and methaemoglobin are formed rapidly (within 2–
3 hours [11,14]) in animals following injection of pro-
panil, consistent with our findings in figure 4. By contrast,
in a case report of human self-poisoning the peak DCA
concentration was observed at 24 hours, which may relate
Concentration-time profile of propanil and DCA in patients during admission Figure 4
Concentration-time profile of propanil and DCA in patients during admission. DCA is indicated by open squares 
with dashed line and propanil is indicated by closed circles and solid line. Note that the scales differ; XT = exchange transfu-
sion.
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to the co-ingestion with carbaryl.[4] The rate of biocon-
version in our patients was variable, in particular the fatal
case where it was prolonged, as shown in figure 4. Inter-
individual differences in esterase activity due to genetics
or co-exposure to other pesticides may explain such differ-
ences. However, there was no history of co-ingestion of
other pesticides and BChE activity was normal (BChE
activity was measured in patients where the elimination of
propanil was prolonged; n = 18).
The specific CYP450 that N-hydroxylates DCA (figure 1)
has not been characterised, but rat studies suggest that this
reaction is saturable (Km = 120 μM [13] which might pro-
long the elimination of DCA in overdose. The highest
concentration of DCA usually exceeded that of propanil;
this probably relates to DCA being slightly less lipophilic
than propanil (logPo/w = 2.69 and 3.07, respectively) and
therefore likely to have a smaller Vd. It is also possible that
in some of the patients the peak propanil concentration
preceded admission and was therefore not observed.
The predominant clinical manifestation is methaemoglo-
binaemia. This occurs due to bioconversion of propanil to
3,4-dichlorophenylhydroxylamine, which is co-oxidised
with oxyhaemoglobin (Fe2+) in erythrocytes to the ferric
state (Fe3+). [11-14] Methaemoglobin is unable to bind
and transport oxygen, inducing a relative hypoxia at the
tissue level despite adequate arterial oxygenation. This
leads to end-organ dysfunction, manifesting particularly
as central nervous system depression, hypotension and
acidosis.[23] However, the mechanism of toxicity may
not be completely attributed to methaemoglobinaemia.
In general, > 70% methaemoglobinaemia is associated
with severe poisoning and death;[23] but in propanil
exposures severe poisoning and death can occur when
methaemoglobinaemia is as low as 40%.[3,5,6,9] It is
therefore possible that toxic mechanisms other than
methaemoglobinaemia may contribute to clinical out-
comes.
Propanil may directly contribute to clinical toxicity. Rat
studies have shown that if the esterases responsible for
propanil metabolism (figure 1) are inhibited, propanil
can induce poisoning in the absence of methaemoglobi-
naemia.[12] Haemolysis and anaemia have also been
reported following acute propanil poisoning, [5-8] which
has been attributed to the hydroxylamine metabolite.[15]
Cellular toxicity induced by the hydroxylamine com-
pound has been attributed to glutathione deple-
tion,[24,25] but in another study intracellular glutathione
was not altered.[26] Other demonstrable toxicity from the
hydroxylamine compound includes lipoperoxida-
tion,[27] myelotoxicity,[28,29] and immune dysfunction
[30,31], however their clinical significance is not known.
Comparison of individual concentration-time profiles of pro- panil and DCA, including the clinical outcome Figure 6
Comparison of individual concentration-time profiles 
of propanil and DCA, including the clinical outcome. 
The median best-fit apparent elimination half life of propanil 
= 3.2 hours (95% confidence interval 2.6 to 4.1 hours). Two 
of these patients were known to receive exchange transfu-
sion and their half-life did not appear to differ from the oth-
ers.
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Admission propanil and DCA plasma concentrations relative to the time post-ingestion and severity of poisoning Figure 8
Admission propanil and DCA plasma concentrations relative to the time post-ingestion and severity of poison-
ing.
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Because the minimum toxic dose has not been deter-
mined and the potential for severe poisoning and death is
high, all oral ingestions should be treated as significant
and monitored for a minimum of 12 hours. Routine clin-
ical observations are sufficient to detect the development
of clinical toxicity. Clinical cyanosis and 'chocolate
brown' coloured blood on white filter paper suggests
methaemoglobinaemia and severity can be monitored
with serial blood gases (including methaemoglobinaemia
and lactate), if available. Pulse oximetry is not usually use-
ful for monitoring methaemoglobinaemia and the
response to treatment.[23] Most do not measure methae-
moglobin and new pulse oximeters that can measure
methaemoglobin have not yet been validated in a clinical
setting with such potentially high readings.[32] It has
been suggested that methaemoglobinaemia should be
used to determine poisoning severity and that measuring
the concentration of propanil is only useful for confirm-
ing exposure.[33] However, in our data propanil and DCA
concentrations did reflect clinical outcomes (table 2, fig-
ure 3 and figure 8). Factors influencing the precision of
this association include patient co-morbidities, documen-
tation by the study doctors or differences in management
such as the use of antidotes, although this cannot be deter-
mined from our data. This approximate concentration-
response relationship reflects the proximity of propanil
and its metabolites with the primary site of toxicity, the
erythrocyte.
Until more data are available it seems reasonable to focus
treatment on reversal of methaemoglobinaemia. Because
the plasma concentration of DCA remains elevated meth-
aemoglobinaemia will persist for a similar time. [3-5]
Methylene blue has a half-life of 5 hours [34] which is
shorter than that of DCA in many patients, figures 4 and
6. Rebound poisoning is therefore likely in severe cases
from a bolus regimen (see figure 9 for example). This
problem can be countered by administration of methyl-
ene blue as a constant infusion. This strategy has been
reported as successful in dapsone poisoning [35-37]
which similarly produces prolonged methaemoglobinae-
mia and has a much longer half-life than methylene
blue.[38,39]
Methylene blue is intermittently unavailable and poten-
tially of low efficacy in some patients so other treatments
should be explored. Possibilities include acetylcysteine,
toluidine blue and CYP450 enzyme inhibitors (eg. cime-
tidine). Acetylcysteine may act directly as an antioxidant
or as a cysteine precursor that aids replacement of intrac-
ellular glutathione. In vitro studies have suggested that
acetylcysteine directly reduces methaemoglobin, but very
high concentrations were used.[40,41] These are equiva-
lent to more than 500-times the dose used for paraceta-
mol poisoning, which would be almost certainly
associated with unacceptable adverse effects. We con-
ducted an in vitro study using 4-DMAP (4-dimethylami-
nophenol [42])-induced methaemoglobin with a more
reasonable concentration of acetylcysteine (1 mM) but
did not find any significant reduction (data not shown).
This has also been demonstrated by others in vitro [43]
including a clinical study using sodium nitrite-induced
methaemoglobin.[44] In contrast, in vitro studies with
3,4-dichlorophenylhydroxylamine have shown that cellu-
lar toxicity is reduced with 1 mM acetylcysteine or 2 mM
ascorbic acid pre-treatment. [24]
Toluidine blue is another phenothiazine dye that in vol-
unteer studies is more effective than methylene blue at
reversing methaemoglobinaemia and has fewer adverse
effects.[45] Co-administration of cimetidine and dapsone
inhibits formation of the hydroxylamine metabolite of
dapsone and methaemoglobin.[16,46-49] A similar effect
is possible for propanil poisoning if DCA interacts with
the same CYP450 enzymes, but no data are available and
it is possible detoxifying enzymes might also be inhibited.
There have been no clinical studies assessing whether such
treatment has a role in clinical management.
Exchange transfusion is a popular treatment for methae-
moglobinaemia in Sri Lanka, particularly if methylene
blue is unavailable or ineffective. For some clinicians it is
the preferred treatment for severe propanil poisoning.[10]
Non-sustained reversal of methaemoglobinaemia by methyl- ene blue (MB) in a patient with acute propanil poisoning  despite multiple bolus doses Figure 9
Non-sustained reversal of methaemoglobinaemia by 
methylene blue (MB) in a patient with acute propanil 
poisoning despite multiple bolus doses. The influence of 
ascorbic acid (Vit C) is not able to be determined from this 
data in the absence of kinetic data for DCA. (Adapted from 
Yamashita et al.[3]).
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The regimen is variable, but exchange of one unit every 1–
2 hours for up to five cycles (usually three or less) was
common in cases of severe poisoning. Exchange transfu-
sion can improve oxygen delivery by donation of erythro-
cytes, although their function is temporarily impaired
post-transfusion due to depletion of 2,3-DPG during stor-
age. [50-53] At the same time free haemoglobin is
removed.
Exchange transfusion may have additional benefits if it
removes a sufficient amount of propanil from the body.
The efficiency of this varies inversely with the proportion
of poison located outside the vascular compartment,
which depends on the Vd. The Vd of propanil is not
known but is expected to be large given that both propanil
and DCA are highly lipid soluble. The uptake and distri-
bution of propanil in the channel catfish is extensive,[54]
which also suggests that the Vd will be large in humans.
From this it may be questioned whether the poison load
will be markedly lowered by a few exchange transfusions.
Further, transfusion reactions such as acute lung injury
may occur which is of concern when tissue oxygenation is
already impaired. Therefore, its use requires careful con-
sideration.
In a single case of acute poisoning treated with combined
haemodialysis and haemoperfusion there was a rapid
decrease in propanil concentration during treatment
(half-life = 1 hour). The authors of this case concluded
that this treatment may be useful in patients with acute
poisoning.[5] Unfortunately, the clearance was not meas-
ured directly. Because the half-life during enhanced elim-
ination was not shorter than that in most of our patients
(eg. figure 4) it does not appear to be particularly useful.
Given that poisoning manifests early post-ingestion and
yet the time to death is usually greater than 24 hours
(table 2 and figure 2) there are ample opportunities for
interventions that prevent death. There are no controlled
clinical or laboratory data available on the effect of any
specific treatment in acute symptomatic propanil poison-
ing, so management is largely empirical. It seems reason-
able that patients should be resuscitated and administered
supportive care (particularly oxygen) as usual. Normogly-
caemia should be ensured since adequate glucose concen-
trations are required for endogenous reduction and
maximising the efficacy of methylene blue.[23]
Despite the lack of evidence, phenothiazine dyes such as
methylene blue should be considered a first-line treat-
ment for methaemoglobinaemia. It should be adminis-
tered to symptomatic patients as frequent bolus doses of
1 mg/kg to a daily dose of up to 7 mg/kg (high doses may
exacerbate methaemoglobinaemia and haemoly-
sis),[45,55,56] although this maximum dose is conserva-
tive. This should be maintained by an infusion titrated to
clinical response. If the response to this treatment is poor
others should be considered, such as exchange transfu-
sion. Other treatments including toluidine blue and ace-
tylcysteine might also be considered as add on treatments
if the patient continues to deteriorate clinically, but there
are no data regarding efficacy. Monitoring of haemo-
globin levels is recommended to detect haemolysis and
folate supplementation may be necessary during the
recovery phase if anaemia is significant.
Given the high mortality from acute propanil poisoning
more research is needed to determine the optimal man-
agement. An area for urgent attention is to better describe
the efficacy of methylene blue in terms of dose and regi-
men (intermittent bolus versus continuous infusion).
Other studies for consideration include the relative effi-
cacy of exchange transfusion, toluidine blue as well as
add-on treatment with acetylcysteine and/or cimetidine.
In addition to death, biomarkers should be measured as
secondary endpoints for mechanistic data, including
changes in methaemoglobinaemia, lactate concentration
and markers of haemolysis. The effect of exchange trans-
fusion on the kinetics of propanil and DCA should also be
determined. Further, the influence of glucose-6-phos-
phate dehydrogenase deficiency (which is prevalent in
parts of Sri Lanka [57,58]) on the response to methylene
blue and clinical outcomes should be considered. It is
generally recommended that methylene blue is not
administered to patients with glucose-6-phosphate dehy-
drogenase deficiency because it is minimally effective, in
addition to exacerbating methaemoglobinaemia and
haemolysis.
Conclusion
The case fatality of propanil is high compared to most
other herbicides and current treatments appear to be inad-
equate. Clinical toxicity is primarily dose-related due to
the metabolites. Because patients with limited clinical tox-
icity on admission may still die or develop severe poison-
ing, close monitoring is necessary. There is a substantial
window of opportunity for interventions prior to death
which should encourage further clinical research. Priori-
ties include characterising the time course of methaemo-
globinaemia, the efficacy of current and alternative
treatments, and the means by which they may be opti-
mised.
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